 
MAINE STATE LEGISLATURE  
 
 
 
The following document is provided by the 
LAW AND LEGISLATIVE DIGITAL LIBRARY  
at the Maine State Law and Legislative Reference Library 
http://legislature.m aine.gov/lawlib 
 
 
 
 
 
 
 
 
 
 
Reproduced from electronic originals 
(may include minor formatting diffe rences from printed original) 
 
 
Printed on recycled paper128th MAINE LEGISLATURE
FIRST REGULAR SESSION-2017
Legislative Document No. 1406
S.P. 484 In Senate, April 11, 2017
An Act  To Promote Prescription Drug Price Transparency
Reference to the Committee on Health  and Human Services suggested and  ordered printed.
HEATHER  J.R. PRIEST
Secretary of the Senate
Presented by Senator VITELLI of Sagadahoc.
Cosponsored by Representative FOLEY of Wells and
Senators: CARPENTER of Aroostook, JACKSON  of Aroostook,  KEIM of Oxford,  
WHITTEMORE of  Somerset, Representatives: MELARAGNO of Auburn,  MOONEN  of 
Portland, PRESCOTT of  Waterboro,  VACHON of Scarborough.

 
 Page 1 - 128LR0994(01) -1 
 Be it enacted by the People of the State of Maine as follows:  1 
Sec. 1.  22 MRSA ยง2698, as enacted by PL 1999, c. 786, Pt. A, ยง3, is repealed and 2 
the following enacted in its place:  3 
ยง2698.  Investigation by Attorney General  4 
1.  Definitions.  As used in this section, unless the context otherwise indicates, the 5 
following terms have the following meanings.  6 
A.  "Course of treatment" means the prescribed regimen of health care treatment for 7 
the usual duration of treatment if treatment duration is typically limited , as approved 8 
for labeling by the United States Department of Health and Human Services, Food 9 
and Drug Administration;  10 
B.  "Qualifying prescription drug" or "drug" means a prescription drug that a 11 
manufacturer has made available in the State and that has c reated a substantial public 12 
interest in understanding the development of the drug's pricing because one or more 13 
of the following has occurred:  14 
(1)  The wholesale acquisition cost is $2,500 or more annually or for a course of 15 
treatment;  16 
(2)  The wholesale a cquisition cost of the drug has increased by 50% or more 17 
over the previous 5 years; or  18 
(3)  The wholesale acquisition cost of the drug has increased by 15% or more 19 
over the previous 12 months.  20 
C.  "Wholesale acquisition cost" means the list price of a manu facturer of a 21 
prescription drug to a wholesaler or direct purchaser in the United States, not 22 
including prompt pay or other discounts, rebates or reductions in price, as reported in 23 
wholesale price guides or other publications of pharmaceutical pricing dat a or as 24 
estimated by the Maine Health Data Organization using the all -payer claims data and 25 
the ingredient cost and list price and dispensing fee information that is submitted to 26 
the Maine Health Data Organization.  27 
2.  Substantial public interest.  The Att orney General shall identify annually 28 
qualifying prescription drugs.  29 
3.  Compilation of list; justification.  The Attorney General shall compile a list of 30 
drugs identified pursuant to subsection 2 and shall list the drugs' percentage of wholesale 31 
acquisiti on cost increase, if any, and make the list available to the public on the publicly 32 
accessible website of the Attorney General.  With regard to each drug included on the list, 33 
the Attorney General shall require the manufacturer of the drug to provide justi fication of 34 
the increase in wholesale acquisition cost, if any, and shall specify the format and content 35 
of the reporting, as determined by the Attorney General to be understandable and 36 
appropriate.  37 
4.  Required information.  The Attorney General shall req uire the manufacturer of 38 
each drug identified pursuant to subsection 2 to provide to the Attorney General, in such 39 
 
 Page 2 - 128LR0994(01) -1 
 form and format and on a schedule determined by the Attorney General, the following 1 
information:  2 
A.  Total cost of production and total cost per dose of the drug;  3 
B.  Research and development costs of the drug, including those costs paid with 4 
public funds, those costs reported as after -tax costs and those costs paid by 3rd 5 
parties;  6 
C.  Marketing and advertising costs of the drug, including thos e costs directed to 7 
consumers, those costs directed to prescribers and the total of those costs directed to 8 
consumers and prescribers in the State;  9 
D.  The retail prices of the drug charged to purchasers outside the United States in 10 
countries that are memb ers of the Organisation of Economic Co -operation and 11 
Development or successor organization;  12 
E.  The retail prices of the drug typically charged to purchasers in the State, including 13 
but not limited to pharmacies, pharmacy chains, pharmacy wholesalers and o ther 14 
direct purchasers; and  15 
F.  True net typical prices charged to pharmacy benefits managers for distribution in 16 
this State, net of any rebate or other payments from the manufacturer to the pharmacy 17 
benefits manager and from the pharmacy benefits manager to the manufacturer.  18 
5.  Report to the Speaker of the House of Representatives and the President of 19 
the Senate.  By December 1st each year, the Attorney General shall provide a written 20 
report to the Speaker of the House of Representatives and the President  of the Senate that 21 
provides information provided by prescription drug manufacturers pursuant to 22 
subsections 3 and 4 and shall post that information on the publicly accessible website of 23 
the Attorney General.  24 
6.  Investigation; enforcement.  The Attorney G eneral shall investigate suspected 25 
cases of violations of this section and may take action to enforce this section.  26 
7.  Required attendance and testimony.  The Attorney General may require, by 27 
summons, the attendance and testimony of witnesses and the prod uction of books and 28 
papers before the Attorney General related to any matter under investigation pursuant to 29 
subsection 6.  The summons must be served in the same manner as summonses for 30 
witnesses in criminal cases, and all provisions of law related to cri minal cases apply to 31 
summonses issued under this section so far as they are applicable.  All investigations or 32 
hearings under this section to which witnesses are summoned or called upon to testify or 33 
to produce books, records or correspondence are public o r private at the choice of the 34 
person summoned.  The expense of the investigation must be paid from the appropriation 35 
provided in Title 5, section 203.  36 
8.  Order of the court.  A Justice of the Superior Court may by order, upon 37 
application of the Attorney General, compel the attendance of witnesses, the production 38 
of books and papers, including correspondence, and the giving of testimony before the 39 
Attorney General in the same manner and to the same extent as before the Superior Court.  40 
Any failure to obey such an order may be punishable by that court as contempt.  41 
 
 Page 3 - 128LR0994(01) -1 
 SUMMARY  1 
This bill amends the law governing profiteering in prescription drugs.  The bill 2 
requires more disclosure of drug production, research and development costs, marketing 3 
and advertising costs  and actual costs paid upon purchase.  The bill allows investigations 4 
by the Attorney General of violations of these provisions.  The bill adds a required 5 
written report from the Attorney General each year.  6 
 
